GGH
FATE icon

GCM Grosvenor Holdings’s Fate Therapeutics FATE Stock Holding History

GCM Grosvenor Holdings’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-495,916
Closed -$1.74M – 21
2024
Q3 		$1.74M Hold
495,916
– – 0.26% 20
2024
Q2 		$1.63M Hold
495,916
– – 0.24% 19
2024
Q1 		$3.64M Hold
495,916
– – 0.56% 18
2023
Q4 		$1.85M Hold
495,916
– – 0.33% 17
2023
Q3 		$1.05M Hold
495,916
– – 0.21% 14
2023
Q2 		$2.36M Hold
495,916
– – 1.02% 12
2023
Q1 		$2.83M Sell
495,916
-541,340
-52% -$3.27M 0.76% 12
2022
Q4 		$10.5M Hold
1,037,256
– – 2.67% 11
2022
Q3 		$23.2M Hold
1,037,256
– – 5.51% 8
2022
Q2 		$25.7M Buy
+1,037,256
New +$28.6M 5.81% 8

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCM Grosvenor Holdings's FATE Position: Q4 2024 in Review

GCM Grosvenor Holdings sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 495,916 shares — an estimated $1.74M sold.

GCM Grosvenor Holdings first reported a position in FATE in Q2 2022 and held it in 10 quarters. The position peaked at $25.7M in Q2 2022. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • GCM Grosvenor Holdings reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GCM Grosvenor Holdings sold 495,916 Fate Therapeutics shares in Q4 2024, an estimated $1.74M.
  • GCM Grosvenor Holdings first reported a position in Fate Therapeutics in Q2 2022 and held it in 10 quarters.
  • GCM Grosvenor Holdings's Fate Therapeutics position peaked at $25.7M in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on GCM Grosvenor Holdings's 13F filing for Q4 2024, filed 14 Feb 2025.